Business Context and Reporting Period
Company: Advanced Polymer Systems, Inc. (APS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1997
APS develops and manufactures patented Microsponge(R) and Polytrap(R) delivery systems for ethical dermatology, over-the-counter (OTC), and personal care products. The company operates a manufacturing facility in Lafayette, Louisiana, and maintains corporate offices in Redwood City, California. In 1997, APS executed a strategic shift to exit direct consumer product marketing, licensing its consumer portfolio to Lander Company to focus on technology licensing and manufacturing.
Key Financial Metrics
| Metric | 1997 | 1996 |
|---|---|---|
| Total Revenues | $18,333,000 | $18,665,000 |
| Product & Technology Revenues | $16,833,000 | $8,197,000 |
| Consumer Products Revenues | $0 | $10,468,000 |
| Milestone Payments | $1,500,000 | $0 |
| Net Loss | $(683,000) | $(9,378,000) |
| Loss Per Share (Basic/Diluted) | $(0.04) | $(0.52) |
| Working Capital | $4,357,000 | $3,800,000 |
| Cash and Cash Equivalents | $8,672,000 | $5,395,000 |
| Total Assets | $24,180,000 | $18,444,000 |
| Long-Term Debt (excl. current) | $3,055,000 | $5,579,000 |
| Shareholders' Equity | $10,241,000 | $5,010,000 |
Gross Profit Margin (excl. milestone): 57% in 1997, compared to 42% in 1996.
Material Changes vs. Prior Period
- Revenue Composition Shift: Product and technology revenues increased 105% to $16.8 million, driven by new product launches (e.g., Retin-A Micro) and technology fees. Conversely, consumer product revenues dropped 100% to zero following the licensing of these assets to Lander Company effective January 1, 1997.
- Profitability Improvement: Net loss decreased 93% to $683,000 from $9.4 million in 1996. This improvement was driven by a 32% reduction in operating expenses and the elimination of a $1.4 million loss on purchase commitments recorded in 1996.
- Expense Reduction: Selling and marketing expenses fell 30% to $3.8 million, and advertising expenses were eliminated entirely ($0 vs. $3.1 million in 1996) as the company ceased direct consumer marketing.
- Liquidity: Cash and cash equivalents increased by $3.3 million to $8.7 million, supported by warrant exercises ($4.95 million) and reduced operating cash burn.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management expects existing cash, receivables, and revenue streams to meet working capital requirements for the foreseeable future. The company is expanding its Lafayette manufacturing facility to meet anticipated volume growth, with completion expected in 1998. Future growth is tied to the success of strategic alliances and the regulatory approval of pipeline products.
Key Risks and Contingencies:
- Regulatory Approval: The melanin-Microsponge sunscreen NDA was found non-approvable pending additional information; FDA approval is not assured.
- Legal Proceedings: Biosource Technologies, Inc. filed a lawsuit in November 1997 claiming damages of at least $1.05 million for unpaid minimum melanin purchases. APS denies liability, asserting obligations are suspended due to lack of FDA approval, and has cross-claimed for contract rescission.
- Concentration Risk: Approximately 51% of trade receivables were concentrated with five customers as of year-end 1997.
- Year 2000 Compliance: The company is reviewing systems for Y2K compliance; while no significant operational problems are expected, implementation delays or costs could adversely affect operations.
Investor Verification Checklist
- Legal Exposure: Verify the status of the Biosource Technologies lawsuit and the potential impact of the $1.05 million claim on future cash flows.
- Regulatory Pipeline: Confirm the status of the melanin-Microsponge sunscreen NDA and the timeline for Phase III trials on 5-Fluorouracil.
- Debt Covenants: Review the terms of the $5.6 million long-term debt, specifically the financial covenants regarding earnings and net worth, given the company's history of net losses.
- Strategic Alliances: Assess the performance of the Johnson & Johnson (Retin-A Micro) and Lander Company agreements as primary revenue drivers.
- Manufacturing Capacity: Confirm the completion and cost of the Lafayette plant expansion scheduled for 1998.